White & Case (New York)

Michael Gallagher

White & Case (New York)
Partner

Michael Gallagher is a trusted commercial litigator and antirust advisor with close to three decades’ experience helping clients navigate their most important challenges. He represents clients in complex antitrust, consumer protection, unfair competition, RICO and false claims matters across a range of industries, including life sciences, insurance, animal health and infant nutrition. His pharmaceutical practice includes representing and counseling clients on critical pricing, reimbursement, marketing, and distribution issues, such as product hopping, reverse payment / pay-for-delay, managed care contracting, co-payment assistance programs, and biosimilar competition. Michael represents clients in jury and non-jury cases before federal and state trial and appellate courts throughout the United States.

Distinctions

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Riyadh)
White & Case (Washington)

Articles

1588 Bulletin

Michael Gallagher, Kristen O’Shaughnessy, Kathryn Jordan Mims, Kevin Adam, Jaclyn Phillips The US President Joe Biden publishes an executive order containing 72 initiatives to address competition concerns in several industries, including pharmaceuticals, biotech, and healthcare

678

Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)

Jack E. Pace, Kristen O’Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

173

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)

Michael Gallagher, Regina Loureiro, Allain Andry, Mark J. Gidley, Kathryn Jordan Mims, Noah A. Brumfield The US DoJ and State Attorney-General propose federal additions to the Price Gouging Framework following the COVID-19 pandemic

125

Price gouging enforcement has largely been left to the States with their patchwork of varying laws—laws that have been invoked sporadically in crises. While the COVID-19 crisis has reportedly led to increased state enforcement, the federal government has taken a larger role, including Justice (...)

Send a message